The antibody response to SARS-CoV-2 increases over 5 months in patients with anosmia/dysgeusia Riccardo Levi^{1,2*}, Leonardo Ubaldi^{1,2*}, Chiara Pozzi², Giovanni Angelotti², Maria Teresa Sandri^{1,2}, Elena Azzolini^{1,2}, Michela Salvatici², Victor Savevski², Alberto Mantovani^{1,2,3} and Maria Rescigno^{1,2,#} ¹Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini, 20090 Pieve Emanuele, MI, Italy. ²Humanitas Clinical and Research Center - IRCCS, Via Manzoni 56, 20089 Rozzano, MI, Italy. ³The William Harvey Research Institute, Queen Mary University of London, London, UK *These authors contributed equally to the work #Corresponding author E-mail: maria.rescigno@hunimed.eu **Humanitas University** Via Rita Levi Montalcini, 4 20090 Pieve Emanuele (MI) Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

29

30

31

32

33

34

35

36

37

38

39

40

41

42

The factors involved in the persistence of antibodies to SARS-CoV-2 are unknown. We evaluated the antibody response to SARS-CoV-2 in personnel from 10 healthcare facilities and its association with individuals' characteristics and COVID-19 symptoms in an observational study. We enrolled 4735 subjects (corresponding to 80% of all personnel) over a period of 5 months when the spreading of the virus was drastically reduced. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. In individuals positive for IgG (≥ 12 AU/mL) at the beginning of the study, we found an increase [p = 0.0002] in antibody response in symptomatic subjects, particularly with anosmia/dysgeusia (OR 2.75, 95% CI 1.753 – 4.301), in a multivariate logistic regression analysis. This may be linked to the persistence of SARS-CoV-2 in the olfactory bulb.

Introduction

43

44

45

46

47

48

49

50

51

52

53

54

76

It is becoming clear that the antibody response to SARS-CoV-2 can last at least 6 months in symptomatic patients ¹, but it seems to decline in asymptomatics ². Similarly, a reduction of antibody response in asymptomatic individuals was shown in a study with a fewer number of individuals (n = 37) ³. The antibody response in COVID-19 patients is associated with the establishment of a memory B cell response which is higher at 6 months ¹, however, it is not clear whether there are features that correlate with this sustained B cell response. We previously showed that an anti-SARS-CoV-2 serological analysis allowed us to follow the diffusion of the virus within healthcare facilities in areas differently hit by the virus ⁴. At 5 months of distance, we analyzed the duration of this antibody response and evaluated whether there were features correlating with maintenance, reduction or increase of the antibody response.

Results

55 56 We assessed the correlation of the rate of antibody increase or decrease with the different analyzed 57 features. In Tables 1 and 2 are reported the rates for individual classes of features with relative 58 statistical analysis. As shown, in the 5 months of observation, females sustained the antibody 59 response better than males (p = 0.01); similarly non-medical healthcare professionals (specifically, healthcare partner operators) had higher antibody rates (p = 0.0009). The levels of antibodies 60 61 increased in hospitals located in the Bergamo area (Castelli and Gavazzeni p < 0.0001) (Table 1) which was more hit by COVID-19 (37 - 43%) of individuals with $IgG \ge 12$. More important, the 62 63 IgG rate in individuals which were positive for IgG (IgG \geq 12 AU/mL; n = 613) at the beginning of 64 the study was increased (p < 0.000001) over time, and this increase was either minor in asymptomatics (n = 91, p = 0.00003) and paucisymptomatics (n = 203) or strong in symptomatics (n = 319, p =65 0.0006) (Table 2). On the contrary, those that had an intermediate IgG titer (3.8 < IgG < 12 AU/mL 66 67 considered as negative) displayed all a significant reduction in IgG rate (p < 0.000001) (Table 1). 68 This may be due to a noise in test analysis as these subjects are considered as negative for SARS-69 CoV-2 IgG according to manufacturer. Many symptoms, including fever, cough, muscle pain, 70 asthenia, tachycardia and anosmia/dysgeusia, correlated with an increase of antibodies in the 5-month 71 observation period (Table 2). 72 As we noticed that the distribution of the rate feature presented a high value of kurtosis (see methods) we restricted the data set to subjects with IgG rates either below the 10^{th} percentile [< -0.033 (n = 73 454)] or above the 90^{th} percentile [> 0.005 (n = 445)] to prevent a bias-variance problem in machine 74 75 learning models. The accuracy of these rates was confirmed by a linear regression analysis. In Figure

1a and 1b are shown the regression diagnostic plots of predicted values against residuals of training

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

and test data according to the threshold (< -0.033 AU/ml*day and > 0.005 AU/ml*day). In Table 3 is shown the Chi-squared analysis for the populations below or above the set threshold rates. We found that as for the previous analysis, males reduced the level of antibodies more than females, even though this difference was no longer statistically significant (p = 0.06). The levels of antibodies increased in hospitals located in the Bergamo area (Castelli and Gavazzeni: p = 0.0032 and p =0.0005, respectively) which was more hit by COVID-19 (37 – 43% of individuals with IgG \geq 12) ⁷ while it decreased in Humanitas Rozzano (p=0.0806) which was less heavily hit (10% of individuals with IgG \geq 12) ⁷ (Table 3). The rate decreased in asymptomatic (65% of subjects fell in the group \leq -0.033; p < 0.000001), remained constant in paucisymptomatic and increased in symptomatic individuals (62% of subjects were in the group > 0.005; p < 0.000001) (Table 4). Interestingly, among the different symptoms, fever, cough, muscle pain, asthenia, dyspnea, tachycardia, chest pain and anosmia/dysgeusia all correlated with a higher number of individuals falling into the group with rate > 0.005, indicating that these symptoms were strongly associated with sustained/increased antibody response (0.000001 , Table 4). Among these, anosmia/dysgeusia was associated with thehighest percentage of subjects presenting with increased IgG rate (69%; p < 0.000001, Table 4). Having observed differences according to sex, role and site, and since many symptoms are linked, we performed a multivariate logistic regression analysis based in a machine learning approach (see methods). We performed a Bagging classifier of 7 logistic analysis on a training (Accuracy = 76.26; ROC AUC = 76.30; Recall = 81.14) and a test dataset (Accuracy = 72.00; ROC AUC = 72.12; Recall = 81.08). In Figure 1c is shown the multivariate logistic regression analysis. We found that the increased rate was associated primarily with anosmia/dysgeusia (regression coefficient=1.0, 95% CI 0.56 - 1.46) and with chest pain (regression coefficient=0.84, 95% CI 0.24 - 1.44), while the decreased rate was associated to subjects with intermediate IgG (3.8 < IgG < 12) (regression coefficient = -1.61, 95% CI -2.03 - -1.0), which may be related to a noise in the instrument testing, and with past neoplasia (regression coefficient = -1.38, 95% CI -2.4 - -0.37). Interestingly, 54% of subjects with chest pain also presented loss of smell/taste while only 22% of subjects with smell/taste dysfunction also had chest pain, suggesting that IgG increase in the symptomatic population is primarily linked to anosmia and dysgeusia (not shown). In figure 1d are shown the odds ratio relative to figure 1c, which for chest pain is 2.32 (95% CI 1.27 – 4.24), for anosmia/dysgeusia is 2.75 (95% CI 1.75 - 4.30), for subjects with intermediate IgG (3.8 < IgG < 12) is 0.2 (95% CI 0.13 - 0.30) and for subjects with past neoplasia is 0.25 (95% CI 0.09 - 0.69). Overall, these results indicate that although many symptoms are associated with an increase of IgG abundance in the observation time, only anosmia/dysgeusia and chest pain are associated to a higher IgG rate in the multivariate logistic

regression analysis. By contrast the population with past neoplasia or intermediate levels of IgG (3.8

< IgG < 12 AU/mL) are the one that display a reduction in IgG.

Discussion

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

We analyzed the 5-month duration of an antibody response to SARS-CoV-2 in personnel from 9 healthcare facilities and an international medical school (Humanitas University) in Northern Italy in areas differently hit by the virus ⁴. We show that the antibody response is stable both in symptomatic and asymptomatic/paucisymptomatic individuals and is increased in females and in non-medical healthcare professionals. Previously, it has been shown in a study conducted in the British population that the antibody response declines of nearly 22% in symptomatic individuals and of 64% in asymptomatic individuals ². However, this study was based on a prick qualitative test and thus the decline may be related to the sensitivity of the test. We also observed that the antibody response declined when we analyzed the group (3.8 < IgG < 12 AU/mL) with IgG between the limit of detection (3.8 AU/mL) and the threshold of positivity (IgG \geq 12 AU/mL), as set by manufacturer. Whether this is linked to a noise of the instrument that may change according to the test or to a real reduction in an antibody response that may or may not be specific to SARS-CoV-2, remains to be established. When we analyzed the extremes, i.e. the individuals with higher rates of antibody increase or decrease (< -0.033 and > 0.005 AU/mL*day) we observed that asymptomatics had higher negative rates while symptomatics tended to continue increasing the antibody levels suggesting that extreme changes in rate separate the symptomatics from the asymptomatics. As during the observation time there was very limited viral diffusion in Northern Italy, as confirmed also by the finding that only 2 individuals became IgG positive and 2981 remained IgG negative throughout the study (all excluded from the analysis), we can conclude that the sustained or augmented antibody response may not be linked to a re-exposure to the virus. In an attempt to address what improved the antibody response, we found that several symptoms were associated to increased rates of antibodies, however, in a multivariate logistic analysis only anosmia/dysgeusia and chest pain were linked with the highest regression coefficients. Chest pain and anosmia are long-lasting symptoms in COVID-19 patients 8. In addition, anosmia and/or dysgeusia are very common as they are found in around 50-70% of subjects affected by COVID-19 9, 10. In our cohort (Table 2), 49% of IgG positive subjects had anosmia/dysgeusia, 28% chest pain and 13.7% both anosmia/dysgeusia and chest pain, suggesting that indeed these two symptoms may, either alone or in combination, associate with IgG increase. We and others previously found that anosmia/dysgeusia together with fever were the symptoms that mostly characterized SARS-CoV-2 exposure 4, 11. In agreement, anosmia and dysgeusia have been proposed to be used to track SARS-CoV-2 diffusion ¹². Interestingly, SARS-

CoV-2 can infect the olfactory epithelium ^{13, 14}, including olfactory sensory neurons, support cells and immune cells, that express the viral entry receptors ACE2 and TMPRSS2 ^{13, 15, 16}. Here, the virus can persist long and induce local inflammation ¹⁴ and olfactory bulb abnormalities ^{17, 18, 19}. In agreement, the loss of smell and taste can persist in individuals even with RT-PCR SARS-CoV-2 negativity in the nasopharyngeal swab ^{14, 20}.

Overall, these data suggest that increased antibody response in patients with anosmia/dysgeusia may be linked to persistence of the virus in the olfactory bulb which through local inflammation and release of antigens, maintains and boosts the antibody response. This study opens new perspectives on the immunity to SARS-CoV-2 and warrants further investigation on the role of anosmia/dysgeusia on antibody response through the design of prospective observational studies coupling the testing of SARS-CoV-2 persistence in the olfactory bulb, loss of smell or taste and antibody titers.

Methods

144

145

146

147

148

149

150

151

152

153

154

155

156

- 157 <u>Study population</u>
- This observational study has been approved by the international review board of Istituto Clinico Humanitas for all participating institutes (clinicaltrial.gov NCT04387929). Accrual was on a
- 13) Humanitas for an participating institutes (enineartifal.gov 1ve 10+36/727). Neeraal was on a
- voluntary basis: it started on April 28^{th} and more than 80% of personnel participated (n = 4735). The
- study foresees 4 blood collections every 3/4 months. 10 different centers participate: Istituto Clinico
- Humanitas (ICH), Rozzano (MI); Humanitas Gavazzeni, Bergamo; Humanitas Castelli, Bergamo;
- Humanitas Mater Domini (HMD), Castellanza (VA); Humanitas Medical Center, HMC, Varese;
- Humanitas University, Pieve Emanuele (MI); Humanitas San Pio X, Milano; Humanitas Cellini,
- Torino; Humanitas Gradenigo, Torino; Clinica Fornaca, Torino. All participants signed an informed
- 166 consent and filled a questionnaire before blood collection. We analyzed 93 features (72 categorical
- and 17 numerical and 4 temporal) including, age, sex, location, professional role, time between
- sample collections, COVID-19 symptoms (fever, sore throat, cough, muscle pain, asthenia,
- anosmia/dysgeusia (loss of smell and taste), gastrointestinal disorders, conjunctivitis, dyspnea, chest
- pain, tachycardia, pneumonia), home exits and smart-working, comorbidities (diabetes, asthma,
- 171 neoplasia, autoimmunity, cardiovascular disorders, hepatic disorders). After excluding for employees
- that became positive for SARS-CoV-2 IgG (n = 2) during the observation period and those that
- dropped from phase I or for which we were missing at least two features, we analyzed 4534
- participants (4.25% drop out). Here we show the results of the end of phase II (second blood
- sampling).

176

177

IgG measure

For the determination of IgG anti SARS-CoV-2, the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia (VC), Italy) was used ⁵. The method is an indirect chemiluminescence immunoassay for the determination of anti-S1 and anti-S2 specific antibodies. According to kit manufacturer, the test discriminates among negative (< 12AU/mL; with 3.8 as the limit of IgG detection) and positive (≥ 12.0 AU/mL) subjects. However, we considered also individuals with IgG comprised between 3.8 and 12 AU/mL (which we called IgG med: 3.8 < IgG < 12.0 AU/mL). Consistency and reproducibility of the antibody test in samples collected in the two time points was confirmed for a limited number of individuals (n = 50) displaying different degrees of IgG positivity.

Statistical analysis and model

178

179

180

181

182

183

184

185

186

187

191

193

194

- We first cleared the dataset by eliminating data from all of those subjects that did not develop an IgG
- response over time (IgG \leq 3.8 at the beginning and at the end of the examination) (n = 2981). We
- then analyzed the rate of antibody response defined as:

192
$$RATE = \underline{IgG \ phase \ II - IgG \ phase \ I} = [AU / mL * day]$$

 $\Delta days$

- Positive rates mean increased antibody response, while negative rates indicate reduction of antibody
- response between the two analyzed time points.
- 197 For statistical analysis, we performed both a univariate and a multivariate analysis. We applied
- 198 Wilcoxon-Mann-Whitney statistical non-parametric test to compare the antibody rate distribution
- between classes of subjects (Table 1 and Table 2).
- We analyzed the distribution of the rate feature and found a high value of kurtosis (461) around the
- 201 median value of 0.016, hence to perform a multivariate analysis we restricted the data set to subjects
- with IgG rates either below the 10th percentile or above the 90th percentile to prevent a bias-variance
- 203 problem in machine learning models and subjected the data to a linear regression analysis between
- the training and test data sets, where the target variable (rate of antibodies) was standardized using
- 205 the Yeo-Johnson method ⁶. We then applied Chi-squared statistical test to evaluate differences
- between classes and the rate thresholds described above (Tables 3 and 4). In order to evaluate the
- 207 possible interactions between features and the rate of antibody response, we developed a multivariate
- approach to perform a binary classification between subjects who increased or decreased the level of
- antibodies. A set of 7 logistic regressions has been applied on data using a bootstrap procedure
- 210 (samples are drawn with replacement) and the output of each classifier has been averaged by a
- 211 Bagging classifier to obtain the final output. The selection of hyperparameters of the machine learning

- 212 model and the feature selection has been performed with a Bayesian optimization approach based on
- cross validation (4 folds, stratified by outcome).
- 215 <u>Data availability</u>

214

218

- 216 Data supporting the findings of this study are available within the paper. All other data are available
- 217 from the corresponding author upon reasonable requests.

219 References

- 220 1. Dan JM, et al. Immunological memory to SARS-CoV-2 assessed for greater than six months
- after infection. *bioRxiv*, 2020.2011.2015.383323 (2020).
- 222 2. Ward H, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community
- 223 study of 365,000 adults. *medRxiv*, 2020.2010.2026.20219725 (2020).
- 224 3. Long QX, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2
- infections. *Nat Med* **26**, 1200-1204 (2020).
- 226 4. Sandri MT, et al. SARS-CoV-2 serology in 4000 health care and administrative staff across
- seven sites in Lombardy, Italy. *medRxiv*, 2020.2005.2024.20111245 (2020).
- 5. Bonelli F, et al. Clinical And Analytical Performance Of An Automated Serological Test That
- Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively. J Clin
- 230 *Microbiol*, (2020).
- 231 6. Yeo IK, Johnson RA. A new family of power transformations to improve normality or
- 232 symmetry. *Biometrika* **87**, 954-959 (2000).
- 233 7. Sandri M, Elena Azzolini, Valter Torri, Sara Carloni, Michele Tedeschi, Massimo Castoldi,
- Alberto Mantovani, Maria Rescigno. IgG serology in health care and administrative staff
- populations from 7 hospital representative of different exposures to SARS-CoV-2 in
- 236 Lombardy, Italy. MedrXiv, (2020).
- 237 8. Carfi A, Bernabei R, Landi F, Group ftGAC-P-ACS. Persistent Symptoms in Patients After
- 238 Acute COVID-19. *JAMA* **324**, 603-605 (2020).
- 9. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and
- Assessment of an Olfactory Route to Brain Infection. *Neuroscientist*, 1073858420956905
- 241 (2020).
- 242 10. Lechien JR, et al. Clinical and epidemiological characteristics of 1420 European patients with
- mild-to-moderate coronavirus disease 2019. *J Intern Med* 288, 335-344 (2020).

- 244 11. Kumar N, Bhartiya S, Desai S, Mutha A, Beldar A, Singh T. Seroprevalence of Antibodies
- 245 Against SARS-CoV-2 Among Health Care Workers in Mumbai, India. Asia Pac J Public
- 246 *Health*, 1010539520977307 (2020).
- 247 12. Pierron D, et al. Smell and taste changes are early indicators of the COVID-19 pandemic and
- political decision effectiveness. *Nat Commun* 11, 5152 (2020).
- 249 13. Brann DH, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory
- system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv 6, (2020).
- 251 14. De Melo GD, et al. COVID-19-associated olfactory dysfunction reveals SARS-CoV-2
- neuroinvasion and persistence in the olfactory system. bioRxiv, 2020.2011.2018.388819
- 253 (2020).
- 254 15. Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2
- Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of
- 256 Cell Types and Trends with Age. ACS Chem Neurosci 11, 1555-1562 (2020).
- 257 16. Chen M, et al. Elevated ACE-2 expression in the olfactory neuroepithelium: implications for
- anosmia and upper respiratory SARS-CoV-2 entry and replication. Eur Respir J 56, (2020).
- 259 17. Politi LS, Salsano E, Grimaldi M. Magnetic Resonance Imaging Alteration of the Brain in a
- Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. *JAMA Neurol* 77, 1028-
- 261 1029 (2020).
- 262 18. Tsivgoulis G, et al. Olfactory bulb and mucosa abnormalities in persistent COVID-19-
- induced anosmia: a magnetic resonance imaging study. Eur J Neurol, (2020).
- 264 19. Laurendon T, et al. Bilateral transient olfactory bulb edema during COVID-19-related
- anosmia. *Neurology* **95**, 224-225 (2020).
- 266 20. Yan CH, Prajapati DP, Ritter ML, DeConde AS. Persistent Smell Loss Following
- Undetectable SARS-CoV-2. Otolaryngol Head Neck Surg 163, 923-925 (2020).

269 Acknowledgments

268

- 270 This work was partially supported by a philantropic donation by Dolce & Gabbana, by the Italian
- 271 Ministry of Health (Ricerca corrente) and by Fondazione Humanitas per la Ricerca.
- We would like to thank all the employees that volunteered to participate to this study, all the nurses
- and personnel that collected the samples and the laboratory technicians that run the serological and
- 274 rinopharyngeal tests. We would also like to thank the Humanitas management and staff, Drs Patrizia
- 275 Meroni, Michele Lagioia and Michele Tedeschi, who warmly supported this study for the safety of
- the employees.

R.L. and L.U.: performed data analysis; C.P.: contributed to data analysis and manuscript writing; G.A. and V.S.: contributed to data analysis; M.T.S.: coordinated and supervised the laboratory

analyses; E.A.: coordinated the recruitment and sampling of subjects (project administration) and

participated in clinical study design; M.S.: carried out the laboratory analyses; A.M.:

conceptualization and funding acquisition; M.R.: conceived the study, analyzed the data and wrote

284 the manuscript.

278

279

280

281

282

283

285

286

287

288

289

Competing interests

Author contribution

The authors declare no competing interests.

Tables

290

291

Table 1. Demographic distribution of antibody rates.

		counts	min	25 perc	50 perc	75 perc	max	mean	St.Dev.	p_value a
	F	1105	-3.39	-0.04	-0.02	0.02	16.32	0.07	0.61	
Sex	M	448	-0.88	-0.04	-0.02	0	10.37	0.03	0.53	0.0139
	21-30	300	-3.39	-0.04	-0.02	0.01	4.51	0.03	0.41	0.2644
	31-40	365	-0.92	-0.04	-0.02	0.01	2.26	0.02	0.21	0.2302
Age	41-50	455	-2.49	-0.04	-0.02	0.03	3.11	0.06	0.37	0.1083
	51-60	309	-0.88	-0.04	-0.01	0.02	16.32	0.1	0.96	0.1442
	60+	124	-0.68	-0.04	-0.02	-0.01	10.37	0.12	0.99	0.0586
	18.5≤ BMI <25	940	-0.92	-0.04	-0.02	0.01	10.37	0.03	0.41	0.3821
	BMI ≥ 30	106	-3.39	-0.05	-0.02	0.14	16.32	0.23	1.69	0.2182
BMI b	25≤ BMI <30	347	-0.57	-0.04	-0.02	0.01	3.11	0.05	0.29	0.3933
	BMI < 18.5	73	-0.22	-0.04	-0.02	0.02	1.27	0.05	0.26	0.3959
4	$IgG \ge 12$	613	-3.39	-0.08	0.02	0.23	16.32	0.18	0.92	2.1 E-10
IgG class	$IgG \le 3.8$	74	0.01	0.01	0.02	0.03	0.08	0.02	0.01	1.5 E-15
phase 1	3.8 < IgG < 12	866	-0.13	-0.03	-0.02	-0.01	0.83	-0.02	0.04	8.0 E-22
	Other c	200	-0.57	-0.04	-0.02	-0.01	16.32	0.09	1.17	0.0116
	Anesthesiologist	19	-0.83	-0.04	-0.02	0.01	0.09	-0.05	0.2	0.4305 b
	Biologist	18	-0.18	-0.05	-0.02	-0.02	0.03	-0.04	0.05	0.0978 b
	Surgeon	67	-0.88	-0.05	-0.02	0.07	0.61	0.02	0.21	0.2653
	Physiotherapist	21	-0.12	-0.04	-0.02	0.01	0.35	0.01	0.1	0.4204
	Nurse	398	-3.39	-0.04	-0.02	0.04	3.11	0.08	0.41	0.0581
	Physician	210	-0.92	-0.04	-0.01	0.02	10.37	0.08	0.75	0.0804
Dala	Healthcare Partner Operator	149	-2.49	-0.03	-0.01	0.17	1.55	0.1	0.38	0.0009
Role	Front office (PARC)	108	-0.32	-0.04	-0.02	0.01	2.55	0.03	0.27	0.2892
	Researcher	50	-1.5	-0.03	-0.02	-0.01	4.51	0.06	0.68	0.1514
	Cleaning service	29	-0.65	-0.03	-0.02	0.03	1.72	0.09	0.41	0.2414
	Transport service	14	-0.39	-0.04	-0.01	0.02	2.22	0.13	0.62	0.4359 b
	Staff	188	-0.4	-0.04	-0.02	-0.01	0.98	0	0.15	0.0026
	Student	20	-0.19	-0.03	-0.02	-0.01	0.21	-0.02	0.08	0.3705 b
	Laboratory technician	31	-0.17	-0.03	-0.01	-0.01	0.51	0.02	0.15	0.3243
	Radiology technician	31	-0.18	-0.03	-0.02	0.01	1.01	0.04	0.22	0.4002
	Other ^c	21	-0.19	-0.04	-0.02	-0.01	2.22	0.08	0.49	0.2080
	Casa di Cura Cellini	51	-0.17	-0.05	-0.03	-0.01	1.27	0.01	0.22	0.0111
	Clinica Fornaca di Sessant	47	-0.4	-0.05	-0.03	0	0.53	0	0.15	0.0833
Site	Humanitas Castelli	87	-0.28	-0.04	0.02	0.21	3.11	0.24	0.62	4.7 E-05
	Humanitas Gavazzeni	313	-0.88	-0.04	-0.01	0.15	10.37	0.13	0.68	0.0001
	Humanitas Gradenigo	109	-2.49	-0.04	-0.02	-0.01	0.67	-0.01	0.27	0.0586
	Humanitas Mater Domini	105	-0.17	-0.03	-0.02	-0.01	0.63	0	0.1	0.3412
	Humanitas Medical Care		-0.19		-0.02	-0.01	0.02	-0.03	0.04	0.0969
	Humanitas Rozzano	667	-3.39	-0.04	-0.02	0	16.32	0.04	0.7	0.0338
	Humanitas San Pio X	98	-0.68	-0.03	-0.02	0	2.39	0.04	0.29	0.2968
	Humanitas University	32	-0.2	-0.04	-0.02	-0.01	0.19	-0.03	0.08	0.0590

^a = Wilcoxon-Mann-Whitney test

b = Some subjects did not indicate their BMI

c = Refers to volunteers and other professionals that operate in several structures

d = Minority class is less or equal to 20 (Wilcoxon-Mann-Whitney test is not reliable)

Table 2. Antibody rates according to symptoms.

			counts	min	25 perc	50 perc	75 perc	max	mean	St. Dev.	p_value a
Class symptoms	Asymptomatic		91	-1.5	-0.13	-0.05	0.09	2.39	0.04	0.5	0.00003
phase 1 (subjects with	Paucisymptomatic		203	-3.39	-0.08	0.02	0.21	4.51	0.14	0.56	0.32865
$IgG \ge 12$)	Symptomatic		319	-2.49	-0.06	0.07	0.28	16.32	0.24	1.16	0.00057
	Fever	No	350	-3.39	-0.09	0.01	0.21	4.51	0.13	0.02725	0.02725
		Yes	263	-2.49	-0.06	0.05	0.25	16.32	0.24		0.02723
	Low-grade fever	No	481	-3.39	-0.08	0.02	0.23	16.32	0.19	0.17265	0.17265
	Low-grade level	Yes	132	-0.39	-0.07	0.05	0.26	2.55	0.14		
	Cough	No	372	-3.39	-0.08	0.01	0.19	16.32	0.14	0.01120	0.01120
	Cougn	Yes	241	-2.49	-0.07	0.07	0.31	10.37	0.24		0.01120
	Sore throath	No	353	-3.39	-0.09	0.02	0.23	16.32	0.19	0.08309	0.09200
	Sore throath	Yes	260	-2.49	-0.07	0.04	0.25	4.51	0.16		0.08309
	Muscle pain	No	299	-1.5	-0.1	0	0.2	4.51	0.13	0.00763	0.00762
		Yes	314	-3.39	-0.06	0.06	0.27	16.32	0.22		0.00763
	Asthenia	No	341	-3.39	-0.1	0	0.21	16.32	0.17	0.00574	0.00574
Symptoms		Yes	272	-2.49	-0.06	0.07	0.25	10.37	0.19		0.00574
phase 1	Anosmia / dysgeusia	No	313	-3.39	-0.12	-0.01	0.2	16.32	0.14	0.00006	0.00006
(subjects with		Yes	300	-0.86	-0.05	0.06	0.28	10.37	0.22		0.00006
$IgG \ge 12$)	Gastrointestinal disorders	No	403	-3.39	-0.08	0.03	0.21	10.37	0.17	0.46477	0.46477
		Yes	210	-2.49	-0.08	0.02	0.25	16.32	0.19		
	Conjunctivitis	No	517	-3.39	-0.08	0.02	0.21	16.32	0.18	0.16050	0.16050
		Yes	96	-2.49	-0.07	0.04	0.32	1.72	0.14		0.16030
	Dyspnea	No	493	-3.39	-0.08	0.02	0.23	16.32	0.16	0.34700	0.34700
		Yes	120	-2.49	-0.07	0.05	0.26	10.37	0.24		0.34700
	Chart nain	No	502	-3.39	-0.08	0.01	0.24	10.37	0.15	0.08088	0.08088
		Yes	111	-0.39	-0.04	0.07	0.22	16.32	0.3		0.08088
	Toobyzoordio	No	512	-3.39	-0.08	0.01	0.21	4.51	0.13	0.02353	0.02353
		Yes	101	-2.49	-0.06	0.08	0.32	16.32	0.4		0.02333
	Pneumonia	No	568	-3.39	-0.08	0.02	0.22	16.32	0.15	0.18692	0.18692
		Yes	45	-0.88	-0.06	0.06	0.38	10.37	0.51	1.69	0.18092
^a = Wilcoxon-Mann-Whitney test											

Table 3. Chi-squared analysis of groups < 10th percentile and > 90th percentile.

312

Sex F 321 340 M 133 105 21-30 93 83 31-40 108 94 41-50 121 142 51-60 88 98 60+ 44 28 18.5 \leq BMI \leq 25 267 255 BMI \geq 30 58 72 25 \leq BMI \leq 30 106 93	0.0627
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.0627
Age $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	
Age $\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.5429
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.3804
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.0970
$BMI = \begin{bmatrix} 18.5 \le BMI < 25 & 267 & 255 \\ BMI \ge 30 & 58 & 72 \\ \hline 25 \le BMI < 30 & 106 & 93 \\ \hline DMI + 10.5 & 106 & 93 \\ \hline \end{bmatrix}$	0.3711
BMI ^a $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.0793
BMI ^a BMI ≥ 30 58 72 25≤ BMI <30 106 93	0.6963
25≤ BMI < 30 106 93	0.1750
DM + 10.5	0.4214
BMI < 18.5 23 25	0.8261
Other b 63 37	0.0109
Anesthesiologist 6 7	0.9701
Biologist 5 2	0.4640
Surgeon 25 21	0.7007
Physiotherapist 6 7	0.9710
Nurse 113 132	0.1255
Physician 56 61	0.6082
Healthcare Partner Operator 38 64	0.0062
Role Front office (PARC) 31 28	0.8494
Researcher 13 9	0.5485
Cleaning service 7 9	0.7698
Transport Service 5 5	0.7747°
Staff 69 44	0.0214
Student 5 4	0.9759°
Laboratory Technician 6 7	0.9701
Radiology Technician 6 8	0.7587
Other b 6 3	0.5223 °
Casa di Cura Cellini 19 8	0.0573
Clinica Fornaca di Sessant 18 12	0.3828
Humanitas Castelli 23 47	0.0032
Humanitas Gavazzeni 97 142	0.0005
Site Humanitas Gradenigo 36 22	0.0918
Humanitas Mater Domini 20 23	0.7041
Humanitas Medical Care 8 3	0.2379°
Humanitas Rozzano 190 160	0.0806
Humanitas San Pio X 27 21	0.5025
Humanitas University 10 4	0.1905°

^a= Some subjects did not indicate their BMI

^b = Refers to volunteers and other professionals that operate in several structures

c = Minority class is less or equal to 5 (chi-square test is not reliable)

Table 4. Chi-squared analysis of groups < 10th percentile and > 90th percentile per symptoms.

315

	,		<10 perc	>90perc	p_value	%Yes<10perc a	%Yes>90perca
	Fever	No	360	284	3.9E-07		
	Tevel	Yes	94	161	3.7L-07	37	63
	Low-grade fever	No	388	359	0.0678		
		Yes	66	86	0.0070	43	57
	Cough	No	335	284	0.0016		
	coug.	Yes	119	161	0.0010	43	58
	Sore throath	No	302	271	0.0923		
		Yes	152	174	0.0725	47	53
	Muscle pain	No	310	246	0.0001		
	masere pam	Yes	144	199	0.0001	42	58
	Asthenia	No	340	268	3.7E-06		
	11011101111	Yes	114	177	5.72 00	39	61
	Anosmia/dysgeusia	No	364	247	4.0E-15		
		Yes	90	198	4.0L 13	31	69
Symptoms	Gastrointestinal	No	336	313	0.2485		
	disorders	Yes	118	132	0.2403	47	53
	Conjunctivitis	No	400	382	0.3633		
	Conjunctivitis	Yes	54	63	0.3033	46	54
	Decommon	No	405	375	0.0370		
	Dyspnea	Yes	49	70	0.0370	41	59
	Cl	No	415	367	0.0001		
	Chest pain	Yes	39	78	0.0001	33	67
	Tachycardia	No	406	371	0.0107		
		Yes	48	74	0.0107	39	61
	Pneumonia	No	440	420	0.0000		
		Yes	14	25	0.0889	36	64
	Total of Symptoms in phase I	Asymptomatic	150	80	3.4E-07	65	35
		Paucisymptomatic	179	158	0.2520	53	47
		Symptomatic	125	207	5.6E-09	38	62
	Chronic Obstructive	No	451	444			I.
	Bronchopneumopathy	Yes	3	1	0.6305 b		
		No	430	412	0.0100		
	Asthma	Yes	24	33	0.2408		
	D 11 11 1	No	413	404	0.0024		
	Dyslipidemia	Yes	41	41	0.9834		
	Past Neoplasia	No	431	438			
		Yes	23	7	0.0063		
	Hypertension	No	401	409			
		Yes	53	36	0.0915		
	Past	No	454	443			
	Coronaropathies	Yes	0	2	0.4702 b		
		No	450	441	h		
	Atrial Fibrillation	Yes	4	4	0.7439 b		
		No	452	445			
Comorbidities	Past Stroke/ TIA	Yes	2	0	0.4878 b		
		No	448	444			
	Steatosis/Cyrrosis	Yes	6	1	0.1359 b		
	Chronic kidney failure	No	453	445			
		Yes	1	0	0.9920 ^b		
		No	452	441			
	Other liver diseases	Yes	2	4	0.6641 b		
	Rheumatological	No	445	431			
	diseases	Yes	9	14	0.3715		
	Otherdiseases	No	418	409			
	of the immune system	Yes	36	36	0.9726		
		No Yes	452				
	Diabetes mellitus			443	0.6305 b		
		Yes	2	445			
	Gotta	No Vac	452	445	0.4878 b		
		Yes	2	0			

^a = Percentage of subjects with symptoms (Yes) per rate class

b = Minority class is less or equal to 5 (chi-square test is not reliable)

Figure

319

320 321

322

323

324

325

326

327




Figure 1: a, Dataset < 10% percentile Regression Diagnostic plot of predicted values against residuals of training and test data; b, Dataset >90% percentile Regression Diagnostic plot of predicted values against residuals of training and test data; c, Barplot with Logistic Regression coefficients for most important features; d, Odds ratio of Logistic Regression with confidence intervals (95%) for the most important features.